便秘(Constipation)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Constipation Overview 8
Therapeutics Development 9
Pipeline Products for Constipation – Overview 9
Pipeline Products for Constipation – Comparative Analysis 10
Constipation – Therapeutics under Development by Companies 11
Constipation – Therapeutics under Investigation by Universities/Institutes 13
Constipation – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Constipation – Products under Development by Companies 18
Constipation – Products under Investigation by Universities/Institutes 19
Constipation – Companies Involved in Therapeutics Development 20
AlbireoPharma 20
Astellas Pharma Inc. 21
AstraZeneca PLC 22
Beech Tree Labs, Inc. 23
Braintree Laboratories, Inc. 24
Daiichi Sankyo Company, Limited 25
Dong-A Socio Group 26
Ironwood Pharmaceuticals, Inc. 27
Kissei Pharmaceutical Co., Ltd. 28
Lipid Pharmaceuticals ehf. 29
Rhythm Pharmaceuticals 30
Sanwa Kagaku Kenkyusho Co., Ltd. 31
Shire Plc 32
SK Biopharmaceuticals Co., Ltd. 33
Sucampo Pharmaceuticals, Inc. 34
Sumitomo Dainippon Pharma Co., Ltd. 35
Synergy Pharmaceuticals, Inc. 36
Teva Pharmaceutical Industries Limited 37
Constipation – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
5-BOIP – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ASP-7663 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BLI-801 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DA-6886 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DS-3801 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DSP-6952 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
elobixibat – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KWA-0711 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
linaclotide – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LP-101 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lubiprostone – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MDT-006 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
plecanatide – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
prucalopride succinate – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
relamorelin – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SK-1202 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Chronic Constipation – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
tenapanor hydrochloride – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Transilon – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
YKP-10811 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Constipation – Recent Pipeline Updates 76
Constipation – Dormant Projects 97
Constipation – Product Development Milestones 98
Featured News & Press Releases 98
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 98
Nov 12, 2014: Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy’s 98
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 99
Oct 24, 2014: Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation 99
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting 101
Oct 09, 2014: Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA 102
Sep 18, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 103
Aug 21, 2014: Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone 103
Jul 14, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 104
May 06, 2014: Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107